SciClone is developing a portfolio of product candidates for development and commercialization in the major pharmaceutical markets and China.

For the U.S. and European pharmaceutical markets, we plan to develop our lead product thymalfasin (ZADAXIN^®) in a phase 3 malignant melanoma clinical trial. For SCV-07, we are conducting a phase 2 trial in oral mucositis and also a phase 2b trial hepatitis C clinical trial. In China, we have exclusive commercialization and distribution rights to DC Bead™, where the product is under regulatory review. Also in China, we have commercialization and distribution rights to an anti-nausea drug ondansetron RapidFilm™ in China and Vietnam, for which it is seeking regulatory approval. 

Click on the image below to enlarge it